AboutLifeTree
About Lifetree - Who We Are Our Philosophy Executive Management Team: Alice A. Jackson, R.N. Lynn R. Webster, MD, FACPM, FASAM Matthew Iverson Sean Kotrady, CCRC, CCRP Neuroscience Research Team: Miroslav "Misha" Bačkonja, MD Mark A. Johnston, MD N. Lee Smith, MD Daniel B. Vine, MD Mary Jane Norman, MD Dennis Thoen, MD Debra F. Hobbins, DNP, APRN, LSAC, CARN-AP
ClinicalResearch
THERAPEUTIC EXPERTISE Clinical Research Abstracts Abuse Liability Analgesia Pain Model Development Lifetree Center for Neuroscience Research Phase 1 Research Sleep Medicine Ophthalmology
Clinical TrialManagement
Clinical Trial Management Data Management Services Interactive Voice Response System Medical and Safety Management Medical Writing Biostatistics and Analysis Services Drug Development Services
PressRoom
Press Releases & News Media Coverage Research Articles Calendar of Events
ContactLifeTree
Contact Lifetree Employment Opportunities For Study Participants For Biopharmaceutical and Device Clients Physicians: Become a Lifetree Investigator
VolunteerFor a Study
Volunteer - Screening Survey Current Research Studies Clinical Research Studies: Alzheimer's Clinical Trial Bunion Removal Chlamydia Home Testing Kit Chronic Pain Chronic Pain from Post-Herpetic Neuralgia Depression Clinical Trial Diabetic Peripheral Neuropathy Drug Abuse Study - Recreational use of Prescription Medications Gonorrhea Home Testing Kit Healthy Males and Females Healthy Seniors Hepatitis C Clinical Trial High Blood Pressure Hypertension Low Back Pain Mild Dementia Migraine Headaches Multiple Sclerosis Opioid Induced Constipation Osteoarthritis of the Hip and or Knee Schizophrenia Clinical Trial Sciatica Suboxone Wisdom Teeth Removal

News & Press Releases

< back to News & Press Releases

Date: Jun 09 2011

Dr. Lynn Webster quoted in NEKTAR® Phase 1 Study

NEKTAR® Phase 1 Novel Opioid Analgesic Candidate Study.

"NKTR-181 is an exciting development in pain management research,” said Lynn R. Webster,MD, Medical Director of Lifetree Clinical Research. "New therapeutics to manage chronic pain without the serious risks associated with existing opioids are desperately needed. A novel opioid therapy, such as NKTR-181, with lower potential for abuse liability and fewer CNS-related side effects than existing opioids provides great promise for pain practitioners looking for safer, more effective pain management. The profile and properties observed with NKTR-181 in the clinic are highly interesting because these properties are inherent to the molecule’s novel structure, which represents a significant potential advance over existing long-acting opioid drugs, which are typically simply re-formulations of traditional opioids.”

Read the entire study (pdf). Read on the web at NEKTAR®'s website.